Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Marshall Lucia to Prostatic Neoplasms

This is a "connection" page, showing publications Marshall Lucia has written about Prostatic Neoplasms.

 
Connection Strength
  
 
 
8.410
  
  1. Ormond DR, Kleinschmidt-DeMasters BK, Cavalcante D, Smith EE, Cramer SD, Lucia MS. Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression. J Neurooncol. 2019 Apr; 142(2):319-325.
    View in: PubMed
    Score: 0.362
  2. Figg WD, Chau CH, Price DK, Till C, Goodman PJ, Cho Y, Varella-Garcia M, Reichardt JK, Tangen CM, Leach RJ, van Bokhoven A, Thompson IM, Lucia MS. Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial. Urology. 2014 Jul; 84(1):127-31.
    View in: PubMed
    Score: 0.261
  3. Lucia MS, Bostwick DG, Somerville MC, Fowler IL, Rittmaster RS. Comparison of Classic and International Society of Urological Pathology 2005 Modified Gleason grading using needle biopsies from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. Arch Pathol Lab Med. 2013 Dec; 137(12):1740-6.
    View in: PubMed
    Score: 0.253
  4. Lucia MS, Bokhoven Av. Temporal changes in the pathologic assessment of prostate cancer. J Natl Cancer Inst Monogr. 2012 Dec; 2012(45):157-61.
    View in: PubMed
    Score: 0.236
  5. Iczkowski KA, Torkko KC, Kotnis GR, Wilson RS, Huang W, Wheeler TM, Abeyta AM, La Rosa FG, Cook S, Werahera PN, Lucia MS. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol. 2011 Jul; 136(1):98-107.
    View in: PubMed
    Score: 0.214
  6. Iczkowski KA, Lucia MS. Current perspectives on Gleason grading of prostate cancer. Curr Urol Rep. 2011 Jun; 12(3):216-22.
    View in: PubMed
    Score: 0.213
  7. Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG, Coltman CA, Thompson IM. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila). 2008 Aug; 1(3):167-73.
    View in: PubMed
    Score: 0.173
  8. Thompson IM, Tangen CM, Lucia MS. The Prostate Cancer Prevention Trial and the future of chemoprevention. BJU Int. 2008 Apr; 101(8):933-4.
    View in: PubMed
    Score: 0.171
  9. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA, Thompson IM. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep 19; 99(18):1375-83.
    View in: PubMed
    Score: 0.165
  10. Lambert JR, Kelly JA, Shim M, Huffer WE, Nordeen SK, Baek SJ, Eling TE, Lucia MS. Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J Cell Physiol. 2006 Sep; 208(3):566-74.
    View in: PubMed
    Score: 0.153
  11. Thompson IM, Lucia MS. Diagnosing prostate cancer: through a glass, darkly. J Urol. 2006 May; 175(5):1598-9.
    View in: PubMed
    Score: 0.150
  12. Thompson IM, Canby-Hagino E, Lucia MS. Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst. 2005 Sep 07; 97(17):1236-7.
    View in: PubMed
    Score: 0.143
  13. Werahera PN, Miller GJ, Torkko K, Crawford ED, Stewart JS, Deantoni EP, Miller HL, Lucia MS. Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models. Hum Pathol. 2004 Jul; 35(7):798-807.
    View in: PubMed
    Score: 0.132
  14. Sakr WA, Lucia MS. Potential pathologic markers for prostate chemoprevention studies. Urol Clin North Am. 2004 May; 31(2):227-35.
    View in: PubMed
    Score: 0.130
  15. Lucia MS, Torkko KC. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol. 2004 Feb; 171(2 Pt 2):S30-4; discussion S35.
    View in: PubMed
    Score: 0.128
  16. Bhasin S, Travison TG, Pencina KM, O'Leary M, Cunningham GR, Lincoff AM, Nissen SE, Lucia MS, Preston MA, Khera M, Khan N, Snabes MC, Li X, Tangen CM, Buhr KA, Thompson IM. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023 12 01; 6(12):e2348692.
    View in: PubMed
    Score: 0.127
  17. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. Molecular characterization of human prostate carcinoma cell lines. Prostate. 2003 Nov 01; 57(3):205-25.
    View in: PubMed
    Score: 0.126
  18. Schenk JM, Till C, Neuhouser ML, Goodman PJ, Lucia MS, Thompson IM, Tangen CM. Differential Biopsy Patterns Influence Associations between Multivitamin Use and Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2022 11 02; 31(11):2063-2069.
    View in: PubMed
    Score: 0.118
  19. Iczkowski KA, Molina M, Egevad L, Bostwick DG, van Leenders GJLH, La Rosa FG, van der Kwast T, Berney DM, Evans AJ, Wheeler TM, Leite KRM, Samaratunga H, Srigley J, Varma M, Tsuzuki T, Lucia MS, Crawford ED, Harris RG, Stricker P, Lawrentschuk N, Woo HH, Fleshner NE, Shore ND, Yaxley J, Bratt O, Wiklund P, Roberts M, Cheng L, Delahunt B. Low-grade prostate cancer should still be labelled cancer. BJU Int. 2022 12; 130(6):741-743.
    View in: PubMed
    Score: 0.117
  20. Furnish M, Boulton DP, Genther V, Grofova D, Ellinwood ML, Romero L, Lucia MS, Cramer SD, Caino MC. MIRO2 Regulates Prostate Cancer Cell Growth via GCN1-Dependent Stress Signaling. Mol Cancer Res. 2022 04 01; 20(4):607-621.
    View in: PubMed
    Score: 0.113
  21. Jillson LK, Rider LC, Rodrigues LU, Romero L, Karimpour-Fard A, Nieto C, Gillette C, Torkko K, Danis E, Smith EE, Nolley R, Peehl DM, Lucia MS, Costello JC, Cramer SD. MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1. Mol Cancer Res. 2021 07; 19(7):1123-1136.
    View in: PubMed
    Score: 0.106
  22. Chadid S, Song X, Schenk JM, Gurel B, Lucia MS, Thompson IM, Neuhouser ML, Goodman PJ, Parnes HL, Lippman SM, Nelson WG, De Marzo AM, Platz EA. Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial. Nutr Cancer. 2022; 74(1):141-148.
    View in: PubMed
    Score: 0.104
  23. Hurwitz LM, Kulac I, Gumuskaya B, Valle JABD, Benedetti I, Pan F, Liu JO, Marrone MT, Arnold KB, Goodman PJ, Tangen CM, Lucia MS, Thompson IM, Drake CG, Isaacs WB, Nelson WG, De Marzo AM, Platz EA. Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2020 10; 13(10):853-862.
    View in: PubMed
    Score: 0.100
  24. Torkko K, Till C, Tangen CM, Goodman PJ, Song X, Schenk JM, Lucia MS, Peters U, van Bokhoven A, Thompson IM, Neuhouser ML. Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2020 06; 13(6):521-530.
    View in: PubMed
    Score: 0.098
  25. Stanton WN, Crawford ED, Arangua PB, La Rosa FG, van Bokhoven A, Lucia MS, Poage WL, Partin A, Maroni P, Werahera PN. Assessment of high-grade prostate cancer risk using prostate cancer biomarkers. Can J Urol. 2020 02; 27(1):10080-10085.
    View in: PubMed
    Score: 0.097
  26. Ihle CL, Provera MD, Straign DM, Smith EE, Edgerton SM, Van Bokhoven A, Lucia MS, Owens P. Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients. J Immunother Cancer. 2019 11 08; 7(1):293.
    View in: PubMed
    Score: 0.096
  27. Tangen CM, Schenk J, Till C, Goodman PJ, Barrington W, Lucia MS, Thompson IM. Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI. Cancer Epidemiol. 2019 12; 63:101619.
    View in: PubMed
    Score: 0.095
  28. Stone NN, Crawford ED, Skouteris VM, Arangua P, Metsinis PM, Lucia MS, La Rosa FG, Werahera PN. The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate. J Urol. 2019 08; 202(2):264-271.
    View in: PubMed
    Score: 0.093
  29. Stone NN, Crawford ED, Skouteris VM, Arangua P, Metsinis PM, Lucia MS, La Rosa FG, Werahera PN. Reply by Authors. J Urol. 2019 08; 202(2):271.
    View in: PubMed
    Score: 0.093
  30. Goodman PJ, Tangen CM, Darke AK, Lucia MS, Ford LG, Minasian LM, Parnes HL, LeBlanc ML, Thompson IM. Long-Term Effects of Finasteride on Prostate Cancer Mortality. N Engl J Med. 2019 01 24; 380(4):393-394.
    View in: PubMed
    Score: 0.091
  31. Dai JY, LeBlanc M, Goodman PJ, Lucia MS, Thompson IM, Tangen CM. Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride. Cancer Prev Res (Phila). 2019 02; 12(2):113-120.
    View in: PubMed
    Score: 0.090
  32. Nir G, Hor S, Karimi D, Fazli L, Skinnider BF, Tavassoli P, Turbin D, Villamil CF, Wang G, Wilson RS, Iczkowski KA, Lucia MS, Black PC, Abolmaesumi P, Goldenberg SL, Salcudean SE. Automatic grading of prostate cancer in digitized histopathology images: Learning from multiple experts. Med Image Anal. 2018 12; 50:167-180.
    View in: PubMed
    Score: 0.088
  33. Lucia MS, Bostwick DG, Bosland M, Cockett AT, Knapp DW, Leav I, Pollard M, Rinker-Schaeffer C, Shirai T, Watkins BA. Workgroup I: rodent models of prostate cancer. Prostate. 1998 Jun 15; 36(1):49-55.
    View in: PubMed
    Score: 0.087
  34. Maccini MA, Westfall NJ, Van Bokhoven A, Lucia MS, Poage W, Maroni PD, Wilson SS, Glod? LM, Arangua P, Newmark J, Steiner M, Werahera PN, Crawford ED. The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer. Prostate. 2018 05; 78(7):506-511.
    View in: PubMed
    Score: 0.085
  35. Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, Lucia MS, Klein EA, Lippman SM, Parnes HL, Thompson IM, Goodman PJ, Tangen CM, De Marzo AM. A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiol Biomarkers Prev. 2017 10; 26(10):1549-1557.
    View in: PubMed
    Score: 0.082
  36. Azizi S, Bayat S, Yan P, Tahmasebi A, Nir G, Kwak JT, Xu S, Wilson S, Iczkowski KA, Lucia MS, Goldenberg L, Salcudean SE, Pinto PA, Wood B, Abolmaesumi P, Mousavi P. Detection and grading of prostate cancer using temporal enhanced ultrasound: combining deep neural networks and tissue mimicking simulations. Int J Comput Assist Radiol Surg. 2017 Aug; 12(8):1293-1305.
    View in: PubMed
    Score: 0.081
  37. Stone NN, Mouraviev V, Schechter D, Lucia MS, Smith EE, Arangua P, Hoenemeyer J, Rosa J, Bawa R, Crawford ED. The 3DBiopsy Prostate Biopsy System: Preclinical Investigation of a Needle, Actuator, and Specimen Collection Device Allowing Sampling of Individualized Prostate Lengths Between 20 and 60?mm. Urology. 2017 Sep; 107:257-261.
    View in: PubMed
    Score: 0.081
  38. Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, De Marzo AM, Drake CG, Platz EA. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate. 2017 Jun; 77(8):908-919.
    View in: PubMed
    Score: 0.080
  39. Tangen CM, Goodman PJ, Till C, Schenk JM, Lucia MS, Thompson IM. Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials. J Clin Oncol. 2016 12 20; 34(36):4338-4344.
    View in: PubMed
    Score: 0.077
  40. Stone NN, Mouraviev V, Schechter D, Goetz J, Lucia MS, Smith EE, Crawford ED. Deflection Analysis of Different Needle Designs for Prostate Biopsy and Focal Therapy. Technol Cancer Res Treat. 2017 10; 16(5):654-661.
    View in: PubMed
    Score: 0.077
  41. Chen H, Liu X, Brendler CB, Ankerst DP, Leach RJ, Goodman PJ, Lucia MS, Tangen CM, Wang L, Hsu FC, Sun J, Kader AK, Isaacs WB, Helfand BT, Zheng SL, Thompson IM, Platz EA, Xu J. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. Prostate. 2016 09; 76(12):1120-9.
    View in: PubMed
    Score: 0.075
  42. Winchester DA, Gurel B, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Thompson IM, Xu J, Zheng SL, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, Drake CG, De Marzo AM, Platz EA. Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial. Prostate. 2016 May; 76(6):565-74.
    View in: PubMed
    Score: 0.073
  43. Murtola TJ, Gurel B, Umbehr M, Lucia MS, Thompson IM, Goodman PJ, Kristal AR, Parnes HL, Lippman SM, Sutcliffe S, Peskoe SB, Barber JR, Drake CG, Nelson WG, De Marzo AM, Platz EA. Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2016 Mar; 25(3):463-9.
    View in: PubMed
    Score: 0.073
  44. Lucia MS, Anzano MA, Slayter MV, Anver MR, Green DM, Shrader MW, Logsdon DL, Driver CL, Brown CC, Peer CW, et al. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res. 1995 Dec 01; 55(23):5621-7.
    View in: PubMed
    Score: 0.073
  45. Nash SH, Till C, Song X, Lucia MS, Parnes HL, Thompson IM, Lippman SM, Platz EA, Schenk J. Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2015 Oct; 24(10):1507-15.
    View in: PubMed
    Score: 0.071
  46. Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, Meeker AK, Lucia MS, Anders RA, DeMarzo AM, Drake CG. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 2015 Dec; 18(4):325-32.
    View in: PubMed
    Score: 0.071
  47. Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippmann SM, Parnes HL, Dluzniewski PJ, Isaacs WB, De Marzo AM, Drake CG, Platz EA. Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Prostate. 2015 Sep; 75(13):1403-18.
    View in: PubMed
    Score: 0.070
  48. Barrington WE, Schenk JM, Etzioni R, Arnold KB, Neuhouser ML, Thompson IM, Lucia MS, Kristal AR. Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol. 2015 Jun; 1(3):342-9.
    View in: PubMed
    Score: 0.070
  49. Umbehr MH, Gurel B, Murtola TJ, Sutcliffe S, Peskoe SB, Tangen CM, Goodman PJ, Thompson IM, Lippman SM, Lucia MS, Parnes HL, Drake CG, Nelson WG, De Marzo AM, Platz EA. Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4?ng?ml(-1), normal DRE and negative for prostate cancer. Prostate Cancer Prostatic Dis. 2015 Sep; 18(3):264-9.
    View in: PubMed
    Score: 0.070
  50. Nash SH, Schenk JM, Kristal AR, Goodman PJ, Lucia MS, Parnes HL, Thompson IM, Lippman SM, Song X, Gurel B, De Marzo A, Platz EA. Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2015 Jul; 8(7):590-6.
    View in: PubMed
    Score: 0.070
  51. Heaphy CM, Gaonkar G, Peskoe SB, Joshu CE, De Marzo AM, Lucia MS, Goodman PJ, Lippman SM, Thompson IM, Platz EA, Meeker AK. Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. Prostate. 2015 Aug 01; 75(11):1160-6.
    View in: PubMed
    Score: 0.070
  52. Rodrigues LU, Rider L, Nieto C, Romero L, Karimpour-Fard A, Loda M, Lucia MS, Wu M, Shi L, Cimic A, Sirintrapun SJ, Nolley R, Pac C, Chen H, Peehl DM, Xu J, Liu W, Costello JC, Cramer SD. Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res. 2015 Mar 15; 75(6):1021-34.
    View in: PubMed
    Score: 0.069
  53. Knez VM, Barrow W, Lucia MS, Wilson S, La Rosa FG. Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature. J Med Case Rep. 2014 Aug 14; 8:275.
    View in: PubMed
    Score: 0.067
  54. Gurel B, Lucia MS, Thompson IM, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman SM, Sutcliffe S, Peskoe SB, Drake CG, Nelson WG, De Marzo AM, Platz EA. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):847-56.
    View in: PubMed
    Score: 0.065
  55. Platz EA, Tangen CM, Goodman PJ, Till C, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Lucia MS, Thompson IM, Kristal AR. Statin drug use is not associated with prostate cancer risk in men who are regularly screened. J Urol. 2014 Aug; 192(2):379-84.
    View in: PubMed
    Score: 0.064
  56. Werahera PN, Jasion EA, Crawford ED, La Rosa FG, Lucia MS, van Bokhoven A, Sullivan HT, Port JD, Maroni PD, Daily JW. Systematic diagnosis of prostate cancer using an optical biopsy needle adjunct with fluorescence spectroscopy. Annu Int Conf IEEE Eng Med Biol Soc. 2014; 2014:2165-8.
    View in: PubMed
    Score: 0.064
  57. Shore N, Concepcion R, Saltzstein D, Lucia MS, van Breda A, Welbourn W, Lewine N, Gustavsen G, Pothier K, Brawer MK. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin. 2014 Apr; 30(4):547-53.
    View in: PubMed
    Score: 0.064
  58. Iczkowski KA, Torkko KC, Wilson RS, Lucia MS, Bostwick DG. Prostatic atrophy: its spatial proximity to carcinoma and intraepithelial neoplasia based on annotation of digital slides. Hum Pathol. 2014 Jan; 45(1):54-8.
    View in: PubMed
    Score: 0.063
  59. Werahera PN, Crawford ED, La Rosa FG, Torkko KC, Schulte B, Sullivan HT, van Bokhoven A, Lucia MS, Kim FJ. Anterior tumors of the prostate: diagnosis and significance. Can J Urol. 2013 Oct; 20(5):6897-906.
    View in: PubMed
    Score: 0.063
  60. Thompson IM, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013 Aug 15; 369(7):603-10.
    View in: PubMed
    Score: 0.062
  61. Neuhouser ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes HL, Tao Y, Figg WD, Lucia MS, Hoque A, Hsing AW, Thompson IM, Pollak M. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prev Res (Phila). 2013 Feb; 6(2):91-9.
    View in: PubMed
    Score: 0.060
  62. Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate. 2013 May; 73(7):778-87.
    View in: PubMed
    Score: 0.059
  63. Werahera PN, Sullivan K, La Rosa FG, Kim FJ, Lucia MS, O'Donnell C, Sidhu RS, Sullivan HT, Schulte B, Crawford ED. Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume. Int J Clin Exp Pathol. 2012; 5(9):892-9.
    View in: PubMed
    Score: 0.059
  64. Rove KO, Debruyne FM, Djavan B, Gomella LG, Koul HK, Lucia MS, Petrylak DP, Shore ND, Stone NN, Crawford ED. Role of testosterone in managing advanced prostate cancer. Urology. 2012 Oct; 80(4):754-62.
    View in: PubMed
    Score: 0.058
  65. Ray R, Banks M, Abuzahra H, Eddy VJ, Persons KS, Lucia MS, Lambert JR, Holick MF. Effect of dietary vitamin D and calcium on the growth of androgen-insensitive human prostate tumor in a murine model. Anticancer Res. 2012 Mar; 32(3):727-31.
    View in: PubMed
    Score: 0.056
  66. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012 Mar 24; 379(9821):1103-11.
    View in: PubMed
    Score: 0.056
  67. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12; 306(14):1549-56.
    View in: PubMed
    Score: 0.055
  68. Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia MS, Platz EA, Figg WD, Hoque A, Hsing A, Neuhouser ML, Parnes HL, Reichardt JK, Santella RM, Till C, Lippman SM. Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila). 2010 Dec; 3(12):1523-33.
    View in: PubMed
    Score: 0.051
  69. Koul HK, Kumar B, Koul S, Deb AA, Hwa JS, Maroni P, van Bokhoven A, Lucia MS, Kim FJ, Meacham RB. The role of inflammation and infection in prostate cancer: Importance in prevention, diagnosis and treatment. Drugs Today (Barc). 2010 Dec; 46(12):929-43.
    View in: PubMed
    Score: 0.051
  70. Flaig TW, Glod? M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate. 2010 Jun 01; 70(8):848-55.
    View in: PubMed
    Score: 0.050
  71. Troyer DA, Lucia MS, de Bru?ne AP, Mendez-Meza R, Baldewijns MM, Dunscomb N, Van Engeland M, McAskill T, Bierau K, Louwagie J, Bigley JW. Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev. 2009 Oct; 18(10):2717-22.
    View in: PubMed
    Score: 0.047
  72. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Klein EA. Chemoprevention of prostate cancer. J Urol. 2009 Aug; 182(2):499-507; discussion 508.
    View in: PubMed
    Score: 0.046
  73. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009 Mar; 181(3):956-62.
    View in: PubMed
    Score: 0.045
  74. Kelly JA, Lucia MS, Lambert JR. p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms. Cancer Lett. 2009 May 08; 277(1):38-47.
    View in: PubMed
    Score: 0.045
  75. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman CA. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 07; 301(1):39-51.
    View in: PubMed
    Score: 0.045
  76. Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia MS, Goodman P, Parnes H, Coltman CA. The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. J Urol. 2008 Aug; 180(2):544-7.
    View in: PubMed
    Score: 0.043
  77. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila). 2008 Aug; 1(3):174-81.
    View in: PubMed
    Score: 0.043
  78. Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Bar?n AE, Lucia MS, Thompson IM, Leach RJ. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Cancer Res. 2008 May 15; 14(10):3223-9.
    View in: PubMed
    Score: 0.043
  79. Song Y, Tangen C, Goodman P, Parnes HL, Lucia MS, Thompson IM, Kristal AR. Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment. Prostate. 2008 Feb 15; 68(3):281-6.
    View in: PubMed
    Score: 0.042
  80. Iczkowski KA, Hossain D, Torkko KC, Qian J, Lucia MS, Wheeler TM, Rewcastle JC, Bostwick DG. Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology. 2008 Jun; 71(6):1166-71.
    View in: PubMed
    Score: 0.042
  81. Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol. 2007 Jul 20; 25(21):3076-81.
    View in: PubMed
    Score: 0.041
  82. Thompson IM, Lucia MS, Redman MW, Darke A, La Rosa FG, Parnes HL, Lippman SM, Coltman CA. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol. 2007 Jul; 178(1):107-9; discussion 110.
    View in: PubMed
    Score: 0.040
  83. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, Coltman CA. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol. 2007 May; 177(5):1749-52.
    View in: PubMed
    Score: 0.040
  84. Thompson IM, Lucia MS, Tangen CM. Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: "what has been will be again, what has been done will be done again; there is nothing new under the sun." ECCLESIASTES 1:9. Int J Epidemiol. 2007 Apr; 36(2):287-9.
    View in: PubMed
    Score: 0.040
  85. Flaig TW, Nordeen SK, Lucia MS, Harrison GS, Glod? LM. Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes. J Urol. 2007 Apr; 177(4):1229-37.
    View in: PubMed
    Score: 0.040
  86. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006 Nov 15; 296(19):2329-35.
    View in: PubMed
    Score: 0.039
  87. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006 Aug 16; 98(16):1128-33.
    View in: PubMed
    Score: 0.038
  88. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006 Apr 19; 98(8):529-34.
    View in: PubMed
    Score: 0.037
  89. Garcia GE, Wisniewski HG, Lucia MS, Arevalo N, Slaga TJ, Kraft SL, Strange R, Kumar AP. 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):980-8.
    View in: PubMed
    Score: 0.037
  90. Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, McConnell J, Roehrborn CG. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol. 2005 Dec; 174(6):2098-104.
    View in: PubMed
    Score: 0.036
  91. Crawford ED, Wilson SS, Torkko KC, Hirano D, Stewart JS, Brammell C, Wilson RS, Kawata N, Sullivan H, Lucia MS, Werahera PN. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int. 2005 Nov; 96(7):999-1004.
    View in: PubMed
    Score: 0.036
  92. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005 Jul 06; 294(1):66-70.
    View in: PubMed
    Score: 0.035
  93. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004 May 27; 350(22):2239-46.
    View in: PubMed
    Score: 0.033
  94. Thompson IM, Albanes D, Basler JW, Crawford ED, Denis LJ, Djavan B, Fleshner N, Johnson-Pais TL, Klein EA, Kristal AR, Lucia MS, Parnes HL, Piazza GA, Platz EA, Pollock BH, Price DK, Reichardt JK, Tangen CM, Tolcher AW, McMann MC. First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement. J Urol. 2004 Feb; 171(2 Pt 2):S3-4.
    View in: PubMed
    Score: 0.032
  95. van Bokhoven A, Caires A, Maria MD, Schulte AP, Lucia MS, Nordeen SK, Miller GJ, Varella-Garcia M. Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines. Prostate. 2003 Nov 01; 57(3):226-44.
    View in: PubMed
    Score: 0.031
  96. Kawata N, Miller GJ, Crawford ED, Torkko KC, Stewart JS, Lucia MS, Miller HL, Hirano D, Werahera PN. Laterally directed biopsies detect more clinically threatening prostate cancer: computer simulated results. Prostate. 2003 Oct 01; 57(2):118-28.
    View in: PubMed
    Score: 0.031
  97. Miller GJ, Miller HL, van Bokhoven A, Lambert JR, Werahera PN, Schirripa O, Lucia MS, Nordeen SK. Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res. 2003 Sep 15; 63(18):5879-88.
    View in: PubMed
    Score: 0.031
  98. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003 Jul 17; 349(3):215-24.
    View in: PubMed
    Score: 0.031
  99. Chadid S, Barber JR, Nelson WG, Gurel B, Lucia MS, Thompson IM, Goodman PJ, Stanczyk FZ, Parnes HL, Lippman SM, De Marzo AM, Platz EA. The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial. Prostate. 2020 08; 80(11):895-905.
    View in: PubMed
    Score: 0.025
  100. Crawford ED, Hirano D, Werahera PN, Lucia MS, DeAntoni EP, Daneshgari F, Brawn PN, Speights VO, Stewart JS, Miller GJ. Computer modeling of prostate biopsy: tumor size and location--not clinical significance--determine cancer detection. J Urol. 1998 Apr; 159(4):1260-4.
    View in: PubMed
    Score: 0.021
  101. Hirano D, Werahera PN, Crawford ED, Lucia MS, DeAntoni EP, Miller GJ. Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: analysis of tumor volume, grade, tumor doubling time and life expectancy. J Urol. 1998 Apr; 159(4):1265-9.
    View in: PubMed
    Score: 0.021
  102. Bayat S, Azizi S, Daoud MI, Nir G, Imani F, Gerardo CD, Yan P, Tahmasebi A, Vignon F, Sojoudi S, Wilson S, Iczkowski KA, Lucia MS, Goldenberg L, Salcudean SE, Abolmaesumi P, Mousavi P. Investigation of Physical Phenomena Underlying Temporal-Enhanced Ultrasound as a New Diagnostic Imaging Technique: Theory and Simulations. IEEE Trans Ultrason Ferroelectr Freq Control. 2018 03; 65(3):400-410.
    View in: PubMed
    Score: 0.021
  103. Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007 Nov; 28(6):763-9.
    View in: PubMed
    Score: 0.010
  104. Cannon GW, Mullins C, Lucia MS, Hayward SW, Lin V, Liu BC, Slawin K, Rubin MA, Getzenberg RH. A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia. J Urol. 2007 Feb; 177(2):610-4; discussion 614.
    View in: PubMed
    Score: 0.010
  105. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res. 1992 Feb 01; 52(3):515-20.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)